Payment overview · 2025
General Payments
$526.12
28 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Calvin Bowen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLOTTE, NC · NPI 1225059611
Verified facts
What the public records show
CMS Open Payments records show Robert Calvin Bowen, M.D. received $526.12 in general payments during 2025 across 28 reported records.
GlaxoSmithKline, LLC. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $196.65 | 37.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.17 | 21.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.74 | 17.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.04 | 8.0% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.27 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.15 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.17 | 3.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.93 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $526.12 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $196.65 | 10 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $196.65 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.74 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.78 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.78 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 21 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
137 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
219 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
40 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 875 | 250 |
| Atorvastatin Calcium | Atorvastatin Calcium | 747 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 727 | 183 |
| Omeprazole | Omeprazole | 707 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 621 | 165 |
| Losartan Potassium | Losartan Potassium | 610 | 177 |
| Gabapentin | Gabapentin | 485 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 485 | 135 |
| Lisinopril | Lisinopril | 354 | 106 |
| Metformin Hcl Er | Metformin Hcl | 316 | 95 |
| Metformin Hcl | Metformin Hcl | 289 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 72 |
| Alprazolam | Alprazolam | 268 | 59 |
| Prednisone | Prednisone | 262 | 176 |
| Furosemide | Furosemide | 238 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 68 |
| Carvedilol | Carvedilol | 222 | 62 |
| Eliquis | Apixaban | 219 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 62 |
| Montelukast Sodium | Montelukast Sodium | 206 | 52 |
| Tramadol Hcl | Tramadol Hcl | 201 | 49 |
| Simvastatin | Simvastatin | 190 | 48 |
| Allopurinol | Allopurinol | 182 | 53 |
| Trazodone Hcl | Trazodone Hcl | 182 | 50 |
| Meloxicam | Meloxicam | 175 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 71 |
| Doxycycline Hyclate | Doxycycline Hyclate | 170 | 142 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 31 |
| Ipratropium Bromide | Ipratropium Bromide | 158 | 42 |
| Ozempic | Semaglutide | 143 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 39 |
| Synthroid | Levothyroxine Sodium | 137 | 36 |
| Potassium Chloride | Potassium Chloride | 134 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 127 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 32 |
| Famotidine | Famotidine | 123 | 35 |
| Sertraline Hcl | Sertraline Hcl | 123 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 41 |
| Finasteride | Finasteride | 117 | 31 |
| Bupropion Xl | Bupropion Hcl | 112 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 27 |
| Jardiance | Empagliflozin | 107 | 28 |
| Mirtazapine | Mirtazapine | 107 | 28 |
| Valacyclovir | Valacyclovir Hcl | 103 | 38 |
| Ezetimibe | Ezetimibe | 97 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 38 |
| Cefdinir | Cefdinir | 92 | 54 |
| Clonazepam | Clonazepam | 92 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 59 |
| Donepezil Hcl | Donepezil Hcl | 83 | 24 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 81 | 81 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 23 |
| Warfarin Sodium | Warfarin Sodium | 80 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 66 |
| Lovastatin | Lovastatin | 78 | 20 |
| Xarelto | Rivaroxaban | 76 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 21 |
| Pregabalin | Pregabalin | 74 | 18 |
| Estradiol | Estradiol | 73 | 23 |
| Fluconazole | Fluconazole | 70 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 21 |
| Azelastine Hcl | Azelastine Hcl | 68 | 28 |
| Glimepiride | Glimepiride | 68 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 22 |
| Mounjaro | Tirzepatide | 65 | 12 |
| Methylprednisolone | Methylprednisolone | 64 | 51 |
| Repatha Sureclick | Evolocumab | 62 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 41 |
| Eszopiclone | Eszopiclone | 60 | 16 |
| Fenofibrate | Fenofibrate | 59 | 18 |
| Spironolactone | Spironolactone | 59 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 18 |
| Liothyronine Sodium | Liothyronine Sodium | 54 | 16 |
| Azithromycin | Azithromycin | 52 | 36 |
| Lorazepam | Lorazepam | 52 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 13 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 42 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 39 |
| Celecoxib | Celecoxib | 38 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 20 |
| Folic Acid | Folic Acid | 35 | 14 |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Nitroglycerin | Nitroglycerin | 35 | 17 |
| Atenolol | Atenolol | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 26 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 26 |
| Valsartan | Valsartan | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Diazepam | Diazepam | 30 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Temazepam | Temazepam | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 23 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 16 |
| Torsemide | Torsemide | 26 | 11 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 25 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Euthyrox | Levothyroxine Sodium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Testosterone | Testosterone | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | 11 |
| Niacin Er | Niacin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $526.12 · 28 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, EVENITY, FARXIGA, Leqembi, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, UBRELVY, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error